Townsquare Media Grows Digital, Reports Q2 Stabilityby Mark Eisenberg 08.08.2024Townsquare Media's digital business drives 52% of revenue, with a focus on programmatic growth despite a slight revenue dip.
California’s Groundbreaking AI Bill Gains Support from Top Expertsby Lilu Anderson 08.08.2024Top AI experts advocate for California's AI Safety Bill, highlighting its necessity to mitigate significant risks and regulate emerging technology.
Why Microsoft Should Keep System Access for Security Vendorsby Lilu Anderson 08.08.2024Exploring the importance of maintaining kernel access for cybersecurity vendors like CrowdStrike despite recent issues.
Best Sports Gear in 2024 Paris Olympicsby Lilu Anderson 08.08.2024Discover how cutting-edge sports gear and technology are revolutionizing athlete performance at the 2024 Paris Olympics.
Ethereum Community Backs New Memecoin Mpeppe (MPEPE)by John Darbie 08.08.2024Discover why the Ethereum community is rallying behind Mpeppe (MPEPE), a new utility memecoin blending blockchain innovation and meme culture.
Black Hat Keynote: CrowdStrike Outage Sparks Global Alarmby Lilu Anderson 08.08.2024The CrowdStrike update mishap and Microsoft outage highlighted the need for cybersecurity preparedness among global leaders.
CVS Health Updates EPS Guidance and Operational Plansby Mark Eisenberg 08.08.2024CVS Health revises full-year EPS guidance to $6.40-$6.55 and plans significant operational improvements to drive future growth.
SCHOTT Group Wins Gold Stevie Awards for Tech Innovationsby Lilu Anderson 08.08.2024SCHOTT honored for microelectronics and pharma solutions, revolutionizing aerospace and drug containment technologies.
Critical Flaws in Alibaba’s T-Head C910 RISC-V Chips Exposedby Lilu Anderson 08.08.2024GhostWrite vulnerability in Alibaba's T-Head C910 chips lets rogue apps read and write physical memory. Fixing it requires disabling vector ...
Rhythm Pharmaceuticals Reports Strong Q2 Results, Driven by IMCIVREEby Mark Eisenberg 07.08.2024Rhythm Pharmaceuticals sees robust Q2 2024 results with $29.1M revenues due to IMCIVREE's success in treating Bardet-Biedl syndrome.